Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
不可切除肝细胞癌患者接受 tremelimumab 联合 durvalumab 治疗和 durvalumab 单药治疗的免疫介导不良事件和总生存期：HIMALAYA III 期随机临床试验
期刊:Hepatology
影响因子:15.8
doi:10.1097/HEP.0000000000001385
Lau, George; Sangro, Bruno; Cheng, Ann-Lii; Kudo, Masatoshi; Kelley, Robin Kate; Tak, Won Young; Gasbarrini, Antonio; Reig, Maria; Lim, Ho Yeong; Tougeron, David; De Toni, Enrico N; Tam, Vincent C; Mody, Kabir; Gong, Jun; Crysler, Oxana V; Sukeepaisarnjaroen, Wattana; Lipatov, Oleg; Morimoto, Manabu; Archambeaud, Isabelle; Burgio, Valentina; Phuong, Le Thi Tuyet; Chao, Yee; Peron, Jean-Marie; Berres, Marie-Luise; Ko, Yoo-Joung; Ran, Di; Makowsky, Mallory; Negro, Alejandra; Abou-Alfa, Ghassan K
